4 Minutes
When diabetes and weight-loss drugs became household names, cancer researchers took notice. A sweeping analysis from the University of Pennsylvania suggests those familiar names — Ozempic, Wegovy, Mounjaro and Zepbound — might carry an unexpected benefit: a substantially lower chance of developing breast cancer.
Scientists mined electronic health records for 111,646 women, aged 45 to 80, all with a body mass index of 25 or higher who underwent breast imaging at Penn Medicine between January 2022 and June 2025. Of those, 15,264 had prescriptions for GLP-1 medications, while 96,382 did not. The team also ran a matched analysis of 30,528 women, pairing each GLP-1 user with a nonuser who had similar age, race, BMI, breast density and diabetes status.
In this dataset, women taking GLP-1 drugs showed about a 30 percent lower chance of being diagnosed with breast cancer. Across the full cohort the reduction in odds was 35.1 percent; in the matched sample the drop was 30.5 percent. The results were presented at the 2026 ASCO Annual Meeting and appear in JCO Oncology Practice.
GLP-1 therapies, which include semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (found in Mounjaro and Zepbound), were created to regulate blood sugar and curb appetite. Their dramatic effects on weight made them front-page news. But biology is rarely one-trick; these drugs also change metabolic signals, reduce markers of chronic inflammation and influence epigenetic pathways that govern gene activity. Any of those actions — alone or in combination — could plausibly nudge the needle on tumor formation.
That said, the investigators are careful. This is observational work, not a randomized clinical trial. The study did not break down outcomes by specific GLP-1 agent, duration of treatment, inherited genetic risk or the cancer subtype and stage. Confounding factors remain possible. Elizabeth McDonald, a radiologist and professor at Penn who helped lead the study, notes the findings add fuel to a research question rather than delivering a verdict: are these drugs preventing cancer, or are they markers of other health behaviors and interventions?
Why does this idea matter? Current prevention options for breast cancer are limited. Screening catches disease earlier. For people at very high inherited risk, prophylactic surgery can dramatically cut odds, but that is an extreme step. Chemoprevention with drugs like tamoxifen helps, yet side effects have kept uptake low. A widely prescribed medication class with even modest preventive benefit would change the landscape.
Researchers are already moving toward more definitive answers. Penn investigators are planning a multisite clinical trial focused on women at elevated risk, including those with prior breast cancer. A controlled study could untangle whether the apparent protective signal in the records is causal and which patients might benefit most.
Science often moves in surprising circles: a pill designed to tame blood sugar and appetite now finds itself under the spotlight for cancer prevention. The road from an observational association to a clinical guideline is long, but the next chapters in this story are in progress. Will GLP-1 medications join screening and lifestyle change as tools to lower breast cancer risk? Time — and trials — will tell.
Source: scitechdaily
Leave a Comment